On Friday, X4 Pharmaceuticals Inc (NASDAQ: XFOR) opened higher 1.50% from the last session, before settling in for the closing price of $0.19. Price fluctuations for XFOR have ranged from $0.17 to $1.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. Company’s average yearly earnings per share was noted -143.86% at the time writing. With a float of $115.02 million, this company’s outstanding shares have now reached $170.95 million.
Let’s look at the performance matrix of the company that is accounted for 143 employees. In terms of profitability, gross margin is 66.41%, operating margin of -1423.58%, and the pretax margin is -1452.48%.
X4 Pharmaceuticals Inc (XFOR) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of X4 Pharmaceuticals Inc is 33.77%, while institutional ownership is 30.32%. The most recent insider transaction that took place on May 17 ’24, was worth 14,654. In this transaction Chief Commercial Officer of this company bought 21,646 shares at a rate of $0.68, taking the stock ownership to the 115,769 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Chief Commercial Officer bought 13,404 for $0.34, making the entire transaction worth $4,598. This insider now owns 129,173 shares in total.
X4 Pharmaceuticals Inc (XFOR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -143.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.26% during the next five years compared to 47.41% growth over the previous five years of trading.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
Check out the current performance indicators for X4 Pharmaceuticals Inc (XFOR). In the past quarter, the stock posted a quick ratio of 3.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.19, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.35 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
X4 Pharmaceuticals Inc (NASDAQ: XFOR) saw its 5-day average volume 1.91 million, a negative change from its year-to-date volume of 3.18 million. As of the previous 9 days, the stock’s Stochastic %D was 35.72%. Additionally, its Average True Range was 0.03.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 2.75%, which indicates a significant decrease from 32.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.45% in the past 14 days, which was lower than the 149.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3056, while its 200-day Moving Average is $0.5318. Nevertheless, the first resistance level for the watch stands at $0.1979 in the near term. At $0.2058, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.2195. If the price goes on to break the first support level at $0.1763, it is likely to go to the next support level at $0.1626. The third support level lies at $0.1547 if the price breaches the second support level.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
There are currently 173,662K shares outstanding in the company with a market cap of 33.00 million. Presently, the company’s annual sales total 2,560 K according to its annual income of -37,450 K. Last quarter, the company’s sales amounted to 1,430 K and its income totaled -39,820 K.
